AKT1 and breast carcinoma: Cao et al. elucidated potential mechanisms of trastuzumab resistance in HER2-positive breast cancer and demonstrated the utility of YAP and p-AKT in predicting the response to neoadjuvant chemotherapy comined with trastuzumab in breast cancer patients [25].